This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Feb 2015

Putting Labelling Where it Should be on the Corporate Agenda

Labelling & Artwork management leader Kallik founder and CEO Neil Gleghorn has been invited to deliver a presentation at CSC Life Sciences’ 'Life Sciences Forum: Innovation for Business Growth’ event.

 

At the major life sciences conference, scheduled for 11–12 February in Malaga, Spain, Gleghorn will present on how the sector can best address the labelling challenges accumulating for players in the industry.

 

Gleghorn will draw on his extensive knowledge and understanding of the pharma industry’s specific challenges (key to his winning a PharmaVOICE 100 place last year, an award that celebrates the most influential people in the life sciences industry).

 

Gleghorn will look at typical artwork and labelling practices before outlining the business context: how pharma is battling rising product recalls, to how the medical device field is being forced to respond to latest UDI regulations to how cosmetics firms are tackling new labelling requirements.

 

This set of circumstances, Gleghorn will argue, means that centralising the creation and management of Labelling and Artwork Management (LAM) needs to be much higher on the C-Suite’s agenda.

 

Gleghorn said: “The amount of regulation and legislation coming our way has never been higher, forcing the need to have a robust, transparent process in place to deal with this compliance.

 

“Members of the pharma community need to make labelling a top priority or face major penalties, as well as suffer inefficiencies in their business.”

 

Kallik has been at the forefront of dealing with these issues, having over a decade helped firms capture and manage labelling-based content digitally so as to transform the way large national and international brands bring products to market.

 

Gleghorn’s commitment to that vision has helped the UK firm become a truly global player, working with some of the world’s biggest companies in regulated markets including the pharmaceutical, medical device, cosmetics and chemicals vertical sectors.

Related News